DDInter875 DDInter1297
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer. Niraparib was approved by the European Commission on November 16, 2017 and by Health Canada on June 27, 2019.
Niraparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Darolutamide
Niraparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Niraparib {u} may lead to a major life threatening interaction when taken with {v} Natalizumab
Niraparib {u} may lead to a major life threatening interaction when taken with {v} Baricitinib
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Niraparib may lead to a major life threatening interaction when taken with Natalizumab
Niraparib may lead to a major life threatening interaction when taken with Baricitinib